Among four clinical studies of endogenous ghrelin in heterogeneous populations of patients with various cancers (including gastric, pancreatic, lung, breast, multiple myeloma, lymphomas, head and neck, rectal, adenocarcinoma and gynecological), one reported increased total ghrelin (Mondello et al. 2014) and one increased acyl ghrelin level (Garcia et al. 2006) in the cancer patients vs controls. Here, GHRL is linked to AL amyloidosis.